417 related articles for article (PubMed ID: 19175541)
1. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease.
Sakai T; Planinsic RM; Mathier MA; de Vera ME; Venkataramanan R
Transpl Int; 2009 May; 22(5):554-61. PubMed ID: 19175541
[TBL] [Abstract][Full Text] [Related]
2. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
[TBL] [Abstract][Full Text] [Related]
3. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
[TBL] [Abstract][Full Text] [Related]
4. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension.
Kähler CM; Graziadei I; Wiedermann CJ; Kneussl MP; Vogel W
Wien Klin Wochenschr; 2000 Jul; 112(14):637-40. PubMed ID: 11008327
[TBL] [Abstract][Full Text] [Related]
5. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
6. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial.
Hiremath J; Thanikachalam S; Parikh K; Shanmugasundaram S; Bangera S; Shapiro L; Pott GB; Vnencak-Jones CL; Arneson C; Wade M; White RJ;
J Heart Lung Transplant; 2010 Feb; 29(2):137-49. PubMed ID: 20022264
[TBL] [Abstract][Full Text] [Related]
7. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
[TBL] [Abstract][Full Text] [Related]
8. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
10. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.
McSwain CS; Benza R; Shapiro S; Hill N; Schilz R; Elliott CG; Zwicke DL; Oudiz RJ; Staszewski JP; Arneson CP; Wade M; Zaccardelli D; McLaughlin V
J Clin Pharmacol; 2008 Jan; 48(1):19-25. PubMed ID: 18094217
[TBL] [Abstract][Full Text] [Related]
11. Treprostinil for pulmonary hypertension.
Vachiéry JL; Naeije R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
[TBL] [Abstract][Full Text] [Related]
12. Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension.
Walkey AJ; Fein D; Horbowicz KJ; Farber HW
Pulm Pharmacol Ther; 2011 Aug; 24(4):421-5. PubMed ID: 21251994
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.
de Jesus Perez VA; Rosenzweig E; Rubin LJ; Poch D; Bajwa A; Park M; Jain M; Bourge RC; Kudelko K; Spiekerkoetter E; Liu J; Hsi A; Zamanian RT
Am J Cardiol; 2012 Nov; 110(10):1546-50. PubMed ID: 22853986
[TBL] [Abstract][Full Text] [Related]
15. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation.
Krowka MJ; Plevak DJ; Findlay JY; Rosen CB; Wiesner RH; Krom RA
Liver Transpl; 2000 Jul; 6(4):443-50. PubMed ID: 10915166
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.
Tapson VF; Gomberg-Maitland M; McLaughlin VV; Benza RL; Widlitz AC; Krichman A; Barst RJ
Chest; 2006 Mar; 129(3):683-8. PubMed ID: 16537868
[TBL] [Abstract][Full Text] [Related]
18. Extracorporeal membrane oxygenation rescue therapy in a case of portopulmonary hypertension during liver transplantation: a case report.
Stratta C; Lavezzo B; Ballaris MA; Panio A; Crucitti M; Andruetto P; Fanelli V; Grosso Marra W; Ranieri MV; Salizzoni M
Transplant Proc; 2013 Sep; 45(7):2774-5. PubMed ID: 24034045
[TBL] [Abstract][Full Text] [Related]
19. Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension.
Reisbig KA; Coffman PA; Floreani AA; Bultsma CJ; Olsen KM
Ann Pharmacother; 2005 Apr; 39(4):739-43. PubMed ID: 15755791
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
Mathier MA; McDevitt S; Saggar R
J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
